Aktis Oncology (NASDAQ:AKTS) Stock Price Up 5.7% – Here’s What Happened

Shares of Aktis Oncology (NASDAQ:AKTS) were up 5.7% during mid-day trading on Tuesday. The company traded as high as $17.31 and last traded at $17.31. 164,301 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 354,639 shares. The stock had previously closed at $16.37.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AKTS. Weiss Ratings cut shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 2nd. BMO Capital Markets assumed coverage on shares of Aktis Oncology in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Wedbush reissued an “outperform” rating and set a $35.00 price objective on shares of Aktis Oncology in a research report on Friday, October 2nd. Finally, Oppenheimer began coverage on Aktis Oncology in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $40.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Aktis Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $35.62.

Aktis Oncology Stock Performance

The firm has a market cap of $930.41 million and a price-to-earnings ratio of -21.13. The firm’s 50 day moving average is $19.30 and its 200-day moving average is $20.88.

Aktis Oncology (NASDAQ:AKTS) last posted its earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.70 million. As a group, research analysts predict that Aktis Oncology will post -1.84 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP acquired a new position in Aktis Oncology during the second quarter valued at approximately $63,372,000. Jupiter Topco LLC acquired a new stake in shares of Aktis Oncology in the second quarter worth $42,359,000. Alyeska Investment Group L.P. acquired a new stake in shares of Aktis Oncology in the second quarter worth $9,347,000. BlackRock Inc. lifted its stake in shares of Aktis Oncology by 7.9% in the second quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock worth $73,431,000 after buying an additional 166,231 shares during the last quarter. Finally, Mirador Capital Partners LP boosted its holdings in shares of Aktis Oncology by 232.9% during the 3rd quarter. Mirador Capital Partners LP now owns 133,558 shares of the technology company’s stock worth $2,600,000 after buying an additional 93,434 shares during the period. Institutional investors and hedge funds own 28.84% of the company’s stock.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.